EGFR mutations occur in approximately 15% of patients with NSCLC adenocarcinoma1
The prevalence of EGFR+ NSCLC varies significantly according to ethnicity1
The highest overall EGFR mutation frequency is observed in Asia Pacific with 47%, and the lowest frequency in Oceania with 12%.2
Prevalence of EGFR mutations across the globe2
EGFR mutations are more common in females, non-smokers, Asians, and patients with adenocarcinoma3
EGFR(+): epidermal growth factor receptor (positive); NSCLC: non-small-cell lung cancer.
- Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4:36–54.
- Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892–911.
- Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–93.